PLURISTEM THERAPEUTICS INC. (NASDAQ:PSTI) Files An 8-K Other Events

28

PLURISTEM THERAPEUTICS INC. (NASDAQ:PSTI) Files An 8-K Other Events
Item 8.01. Other Events.


On June 20, 2017, the registrant announced that, due to a recently adopted Chinese policy relating to outbound investments by Chinese companies, the registrant and China-based Innovative Medical Management Co. Ltd., or Innovative, terminated their plan for the execution of definitive agreements relating to the previously announced proposed investment of $30,000,000 by Innovative.



About PLURISTEM THERAPEUTICS INC. (NASDAQ:PSTI)

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s products include PLX-PAD and PLX R18. The Company’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company’s PLX products are administered using a standard needle and syringe. The Company’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases.

An ad to help with our costs